Neoral/cyclosporine-based immunosuppression

The introduction of cyclosporine (CsA) has been a major advance. Its use pa ved the way for successful programs in heart, lung, liver, kidney, and kidn ey-pancreas transplantation. The recent introduction of Neoral has overcome many of the problems associated with the use of Sandimmune (Novartis, Base l, Switzerland), including poor bioavailability, dependence on bile for abs orption, and need for intravenous CsA early in the postoperative period, Th e use of Neoral has resulted in (1) a marked reduction in the incidence of acute cellular rejection, (2) ability to discontinue steroid therapy in the early posttransplantation period, and (3) low toxicity profiles. In direct comparison with tacrolimus, Neoral was equally efficacious and less toxic. This is even more impressive when one now realizes the monitoring of Neora l has been inadequate, and with more sensitive monitoring tools, including peak CsA level; a surrogate marker for C-max, CsA blood concentrations 2 ho urs after drug intake; or area under the CsA time-concentration curve, reje ction rates may be improved, with improvement in toxicity profiles. Copyrig ht (C) 1999 by the American Association for the Study of Liver Diseases.